US009636394B2

(12) **United States Patent**
D'Hondt et al.

(10) **Patent No.: US 9,636,394 B2**
(45) **Date of Patent: May 2, 2017**

(54) **PROCESS FOR PRODUCING INFLUENZA VACCINE**

(75) Inventors: **Erik Jozef D'Hondt**, Rixensart (BE); **Hans Bernd Engelmann**, Dresden (DE)

(73) Assignees: **GLAXOSMITHKLINE BIOLOGICALS SA**, Rixensart (BE); **GLAXOSMITHKLINE BIOLOGICALS, NIEDERLASSUNG DER SMITHKLINE BEECHAM PHARMA GMBH & CO KG.**, Dresden (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 252 days.

(21) Appl. No.: **13/503,859**

(22) PCT Filed: **Oct. 25, 2010**

(86) PCT No.: **PCT/EP2010/066083**

§ 371 (c)(1),
(2), (4) Date: **Apr. 25, 2012**

(87) PCT Pub. No.: **WO2011/051235**

PCT Pub. Date: **May 5, 2011**

(65) **Prior Publication Data**

US 2012/0219587 A1 Aug. 30, 2012

Related U.S. Application Data

(60) Provisional application No. 61/329,230, filed on Apr. 29, 2010.

(30) **Foreign Application Priority Data**

Oct. 27, 2009 (GB) 0918830.1

(51) **Int. Cl.**

A61K 39/145	(2006.01)
C12N 7/00	(2006.01)
A61K 39/12	(2006.01)
A61K 39/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/145*** (2013.01); ***A61K 39/12*** (2013.01); ***C12N 7/00*** (2013.01); *A61K 2039/55566* (2013.01); *C12N 2760/16134* (2013.01); *C12N 2760/16151* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,650,155	A	7/1997	Cornelius et al.
5,667,784	A	9/1997	Cornelius et al.

FOREIGN PATENT DOCUMENTS

DE	155875		7/1983
EP	0382271	B1	1/1990
WO	WO 95/17210		6/1995
WO	WO 02/097072	*	12/2002
WO	WO 02/097072	A2	12/2002
WO	WO 03/076601		9/2003
WO	WO 2006/100109		9/2006
WO	WO 2008/129058		10/2008
WO	WO 2009/029695	*	3/2009
WO	WO 2009/029695	A1	3/2009
WO	WO 2009/115917		9/2009

OTHER PUBLICATIONS

Beyer, et al., "Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines. A review and meta-analysis of the literature", Clin Drug Invest., 15:1-12, 1998.

Crabb, et al., "The determination of polyoxyethylene nonionic surfactants in water at the parts per million level", J. Amer. Oil Chem. Soc., 41:752-755,1964.

EMA/CHMP/BWP/214/96, Committee for Proprietary Medicinal Products (CPMP)."Note for harmonization of requirements for influenza vaccines", 1997.

EMA/CHMP/VWP/263499/2006, "Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context", 2007.

EMA/CHMP/VWP/40560/2014, "Explanatory note on the withdrawal of the Note for guidance on harmonisation of requirements for influenza vaccines and of the core SmPC/PL for inactivated seasonal influenza vaccines", 2014.

Fouchier, et al., Characterization of a Novel Influenza A Virus Hemagglutinin Subtype (H16) Obtained from Black-Headed Gulls, J. Virol., 79:2814-2822, 2005.

Greff, et al., "A colorimetric method for the determination of parts/million of nonionic surfactants", J. Amer. Oil Chem. Soc., 42:180-185, 1965.

Lina, et al, "A TritonX-100-split virion influenza vaccine is safe and fulfils the committee for propriety medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in children adults and the elderly", Biologicals 28:95-103, 2000.

Webster, et al., "Evolution and ecology of influenza A viruses", Microbiol.Rev., 56:152-179, 1992.

Wood et al., International collaborative study of single radial diffusion and immunoelectrophoresis techniques for the assay of haemagglutinin antigen of influenza virus, J. Biol. Stand. 9:317-330, 1981.

Wood, et al., "An improved single radial immunodiffusion technique for the assay of influenza haemagglutinin antigen: Adaptation for potency determination of inactivated whole virus and subunit vaccines", J. Biol. Stand., 5:237-247, 1977.

* cited by examiner

Primary Examiner — Shanon A Foley
Assistant Examiner — Myron Hill
(74) *Attorney, Agent, or Firm* — Natalie A. Lissy

(57) **ABSTRACT**

A process for producing a split influenza virus preparation or subunit influenza preparation comprising the steps of: (i) providing a whole virus preparation; (ii) splitting the whole virus preparation in the presence of a first detergent; (iii) adding t-octylphenoxypolyethoxyethanol (TRITON X-100™) to the resulting split virus preparation; and (iv) filtering the split virus preparation.

18 Claims, 9 Drawing Sheets